Portal hypertension

被引:11
作者
Garcia-Tsao, G [1 ]
机构
[1] Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06520 USA
关键词
D O I
10.1097/00001574-200205000-00009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Portal hypertension is the main complication of cirrhosis and is responsible for its most common complications: variceal hemorrhage, ascites, and portosystemic encephalopathy. Portal hypertension is the result of increased intrahepatic resistance and increased portal venous inflow. Vasodilatation (splanchnic and systemic) and the hyperdynamic circulation are hemodynamic abnormalities typical of cirrhosis and portal hypertension. Gastroesophageal varices result almost solely from portal hypertension, although the hyperdynamic circulation contributes to variceal growth and hemorrhage. Ascites results from sinusoidal hypertension and sodium retention, which is in turn secondary to vasodilatation and activation of neurohumoral systems. Hepatic hydrothorax results from the passage of ascites across the diaphragm and into the pleural space. The hepatorenal syndrome represents the result of extreme vasodilatation with an extreme decrease in effective blood volume that leads to maximal activation of vasoconstrictive systems, renal vasoconstriction, and renal failure. Spontaneous bacterial peritonitis is a potentially lethal infection of ascites that occurs in the absence of a local source of infection. Portosystemic encephalopathy is a consequence of both portal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency resulting in the accumulation of neurotoxins in the brain. (C) 2002 Lippincott Williams Wilkins, Inc.
引用
收藏
页码:351 / 359
页数:9
相关论文
共 51 条
[1]
Allard JP, 2001, AM J GASTROENTEROL, V96, P2442, DOI 10.1111/j.1572-0241.2001.04051.x
[2]
Endocannabinoids acting at vascular CB, receptors mediate the vasodilated state in advanced liver cirrhosis [J].
Bátkai, S ;
Járat, Z ;
Wagner, JA ;
Goparaju, SK ;
Varga, K ;
Liu, J ;
Wang, L ;
Mirshahi, F ;
Khanolkar, AD ;
Makriyannis, A ;
Urbaschek, R ;
Garcia, N ;
Sanyal, AJ ;
Kunos, G .
NATURE MEDICINE, 2001, 7 (07) :827-832
[3]
Bacterial infection in patients with advanced cirrhosis:: a multicentre prospective study [J].
Borzio, M ;
Salerno, F ;
Piantoni, L ;
Cazzaniga, M ;
Angeli, P ;
Bissoli, F ;
Boccia, S ;
Colloredo-Mels, G ;
Corigliano, P ;
Fornaciari, G ;
Marenco, G ;
Pistarà, R ;
Salvagnini, M ;
Sangiovanni, A .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (01) :41-48
[5]
Early administration of vapreotide for variceal bleeding in patients with cirrhosis [J].
Calés, P ;
Masliah, C ;
Bernard, B ;
Garnier, P ;
Silvain, C ;
Szostak-Talbodec, N ;
Bronowicki, J ;
Ribard, D ;
Botta-Fridlund, D ;
Hillon, P ;
Besseghir, K ;
Lebrec, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (01) :23-28
[6]
Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats [J].
Castañeda, B ;
Morales, J ;
Lionetti, R ;
Moitinho, E ;
Andreu, V ;
Pérez-del-Pulgar, S ;
Pizcueta, P ;
Rodés, J ;
Bosch, J .
HEPATOLOGY, 2001, 33 (04) :821-825
[7]
The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation [J].
Córdoba, J ;
Alonso, J ;
Rovira, A ;
Jacas, C ;
Sanpedro, F ;
Castells, L ;
Vargas, V ;
Margarit, C ;
Kulisewsky, J ;
Esteban, R ;
Guardia, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (05) :598-604
[8]
Octreotide for acute esophageal variceal bleeding: A meta-analysis [J].
Corley, DA ;
Cello, JP ;
Adkisson, W ;
Ko, WF ;
Kerlikowske, K .
GASTROENTEROLOGY, 2001, 120 (04) :946-954
[9]
Pharmacological treatment of portal hypertension: An evidence-based approach [J].
D'Amico, G ;
Pagliaro, L ;
Bosch, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (04) :475-505
[10]
Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis [J].
Das, A ;
Dhiman, RK ;
Saraswat, VA ;
Verma, M ;
Naik, SR .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (05) :531-535